GVS, a provider of advanced filtration solutions for critical applications, agreed to acquire Puerto Rico-based manufacturing operations of Haemonetics, a global medical technology company focused on delivering innovative hematology solutions. This transaction is expected to close in the second quarter of calendar 2020, subject to the satisfaction of customary closing conditions. Financial terms were not disclosed. "We are honored that Haemonetics, an industry leader and one of our long-term clients, has chosen GVS for this strategic partnership, which is testament to our technological and process capabilities. This collaboration will provide us with a new channel for R&D, stimulating the introduction of new products, ideas and solutions for the blood filtration market," Massimo Scagliarini, GVS CEO.